South African health officials said Sunday they’re pausing the country’s rollout of AstraZeneca’s coronavirus vaccine after a study showed it offered reduced protection from the Covid-19 variant first identified there.
During a briefing on Sunday, South Africa Minister of Health Dr. Zweli Mkhize said the hold would be temporary while scientists figure out how to most effectively deploy the AstraZeneca vaccine.
Mkhize said South Africa will move forward with the deployment of vaccines made by Pfizer/BioNTech and Johnson & Johnson.
Early data released Sunday suggest two doses of the Oxford/AstraZeneca Covid-19 vaccine provided only “minimal protection” against mild and moderate Covid-19 from the variant first identified in South Africa.
Viral neutralization against the B. 1. 351 variant was “substantially reduced” when compared to the earlier coronavirus strain, researchers said in a news release.
Details of the study by researchers from South Africa’s University of Witwatersrand and others, as well as from the University of Oxford, were shared in a press release.
A company spokesperson said in a statement Saturday it is working with Oxford University to adapt the vaccine against the B. 1. 351 variant and it would advance it through clinical development so “it is ready for Autumn delivery should it be needed. “
On Sunday, Maria Van Kerkhove, World Health Organization’s technical lead for Covid-19, said the WHO’s independent vaccine panel will meet Monday to discuss the AstraZeneca vaccine and what the new study means for vaccines going forward.
Van Kerkhove said on CBS’ “Face the Nation” that “some preliminary studies suggesting reduced efficacy.
